ZURA

Zura Bio is a clinical-stage autoimmune/inflammatory biotech with no approved products and, by its own MD&A, zero product revenue since inception — 'we do not have any product candidates approved for sale and have not generated any revenue from product sales.' Every dollar of value rests on unproven pipeline candidates (TibuSURE, dosed from Dec 2024; TibuSHIELD, from May 2025) tied to the 2022 Lilly license. For a self-directed retail investor, the outcome is a coin-flip on trial readouts you cannot handicap from a 10-K — the textbook 'unknowable risk' case.

The balance sheet is clean but shrinking. Cash fell 38% to $109M while the FY2025 net loss widened to -$68.7M (from -$52.4M) and operating cash burn hit -$64.8M — a ~130% deterioration YoY. That implies well under two years of runway before more capital is needed, and the company explicitly warns it plans to 'substantially increase' R&D (already +72.5% to $42.1M) as trials scale. Debt is negligible (liabilities/equity 0.12x), so the funding will come from equity — and it already is: shares outstanding jumped 38.8% to 94.9M, including ATM sales at just $1.75 in Q1 2025 and stacked pre-funded warrant placements. Diluted EPS worsened to -$1.06 (-76.7%) and ROE is -67.6% against a $224.5M accumulated deficit.